This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. TotalHealthRD.com is a health information website — not a medical practice. Individual results vary. Consult your healthcare provider before starting any supplement. These statements have not been evaluated by the Food and Drug Administration.
By TotalHealthRD.com Editorial Team
Quick Answer: A CBD product label should disclose: per-serving CBD milligrams (not just a per-bottle total), the formulation type (full-spectrum, broad-spectrum, or isolate), and a link to a third-party Certificate of Analysis (COA) that confirms what is actually in the product. Without these three elements, you cannot verify potency, confirm THC content, or compare the product to any published research. This guide walks through exactly how to read each piece — and what common red flags look like.
Most people buying CBD gummies are doing so without a clear framework for evaluating what they are actually purchasing. The CBD supplement market is largely self-regulated — brands set their own labels, and no federal agency reviews those labels for accuracy before a product reaches store shelves or an order confirmation email. That does not mean all CBD products are untrustworthy. It means the burden of verification falls on the buyer.
This guide covers the four things every CBD buyer should check before placing an order, what the findings mean, and what specific language signals a transparency problem worth knowing about.
Why CBD Labels Are Not Self-Verifying
Dietary supplements, including hemp-derived CBD products, are regulated by the FDA under the Dietary Supplement Health and Education Act (DSHEA). Under DSHEA, manufacturers are responsible for ensuring their products are safe and accurately labeled — but the FDA does not review or approve supplement labels before products go to market. The FDA's enforcement role is post-market: it takes action when problems are identified after consumers are already buying and using a product.
For CBD specifically, the regulatory picture is more complex because cannabidiol exists in a legal gray area between dietary supplement and drug (Epidiolex, the FDA-approved pharmaceutical form of CBD, is a drug). The FDA has not issued final rules establishing a clear regulatory pathway for CBD as a dietary supplement as of 2026. This means the label accuracy oversight that applies to pharmaceuticals does not apply to CBD gummies.
The practical result: independent testing has repeatedly found that CBD products frequently contain different amounts of CBD than their labels state — sometimes more, sometimes less, sometimes negligible amounts. A 2017 study in JAMA (Bonn-Miller et al., PMID: 29084320) tested 84 commercially available CBD products and found only 31% were accurately labeled within 10% of their stated CBD content. The landscape has improved since 2017 as the industry has matured, but the fundamental verification gap remains. Third-party testing is the only solution available to consumers.
How to Read the Supplement Facts Panel
The Supplement Facts panel is the regulated portion of a CBD label — the section that must, by law, disclose serving size and ingredient amounts. Start here before reading any marketing claims elsewhere on the packaging or website.
What you are looking for: the serving size stated clearly (e.g., “1 gummy”), the CBD amount per serving stated in milligrams (e.g., “25mg CBD”), and the number of servings per container. These three pieces let you calculate the per-dose amount and verify the total against the per-bottle claim. If a label states “1000MG” prominently on the front and the Supplement Facts panel shows 30 servings at 33mg each — that is consistent. If the Supplement Facts panel shows only a per-bottle total without a per-serving breakdown, the per-dose amount is not disclosed.
Products that list only a per-bottle total (e.g., “500MG per bottle”) without disclosing per-gummy content leave you unable to track your daily intake or compare the product to any published clinical research, which typically reports findings in per-day milligram doses. This is a transparency gap. It is not illegal, but it is a meaningful limitation for any buyer trying to make an informed decision. The CBD research overview on this site covers the dose ranges used in published human studies — having a per-serving disclosure is necessary before that information is applicable to any specific product.
How to Read a Certificate of Analysis
A Certificate of Analysis (COA) is a laboratory test report from an independent third-party lab — meaning a lab with no financial relationship to the brand — that tested a specific batch of the product. A COA confirms what is actually in the product, as opposed to what the label claims. For a CBD product, a complete COA should cover three areas.
Cannabinoid profile: This section shows measured milligrams of CBD, THC, and often other cannabinoids (CBG, CBN, CBC) per serving or per gram. The CBD amount should match the label within a reasonable tolerance (±10-15% is industry-standard). The delta-9 THC amount should be below 0.3% by dry weight for federally legal hemp products. For broad-spectrum products, THC should be non-detected (ND). For isolate products, all cannabinoids except CBD should be non-detected or minimal. If a product claims to be “full-spectrum” but the COA shows non-detected THC, the product is not true full-spectrum — it may be broad-spectrum or isolate with a marketing label mismatch.
Contaminant screening: This section covers heavy metals (lead, arsenic, cadmium, mercury), pesticides, microbial contamination (E. coli, Salmonella, total yeast and mold), and residual solvents from the extraction process. All of these should show either “pass” or non-detected results. Hemp is a bioaccumulator — it absorbs compounds from the soil it is grown in, which is why heavy metal screening matters in CBD products specifically.
Batch number verification: A COA is only valid for the specific batch it tested. The batch number on the COA should match a batch number on the product you are buying. Brands that display a single COA for a product that was tested years ago are not providing current batch verification. Ask the brand directly if the COA displayed corresponds to current production batches if the date on the COA is more than 12 months old.
For comparison of which CBD products provide publicly accessible, current COAs — and which do not — the full-spectrum CBD gummies comparison on this site documents COA availability as a standard evaluation dimension.
Full-Spectrum vs. Broad-Spectrum vs. Isolate: What It Means on a Label
These three terms describe how much of the hemp plant's original compound profile remains in the finished extract, and they have practical implications for THC exposure and drug testing.
Full-spectrum CBD retains all naturally occurring cannabinoids, including trace THC (under 0.3% delta-9 THC), along with terpenes and flavonoids from the hemp plant. The theoretical benefit is the “entourage effect” — the idea that these compounds work more effectively together than in isolation. The practical implication is that daily use of full-spectrum CBD can produce cumulative trace THC accumulation in fat tissue, which may generate detectable THC metabolites in a drug test. This is not a reason to avoid full-spectrum CBD, but it is a reason to know what you are taking if drug testing is part of your life.
Broad-spectrum CBD has undergone additional processing to remove THC while retaining other minor cannabinoids and terpenes. It is the middle option — some entourage-effect compounds present, without the THC. COA cannabinoid profile for broad-spectrum should show non-detected THC.
CBD isolate is pure cannabidiol — all other compounds removed. The COA cannabinoid profile should show only CBD, with all other cannabinoids non-detected. Isolate products offer the most predictable dosing because there are no interacting minor cannabinoids, but they lack any potential entourage-effect benefit.
A product that describes itself as both “full spectrum” and “THC-free” is using contradictory language. True full-spectrum hemp contains trace THC by definition. When both descriptions appear on the same product — in marketing materials, on the website, or on the label — that is a signal to request a COA before purchasing rather than relying on either claim.
The Dose Math: Applying the Label to the Research
Once you have a per-serving CBD milligram amount and a COA confirming it, you can apply the published research to your product choice. The relevant question is: does this product's per-serving dose fall within the range that produced effects in published human studies?
For anxiety and stress outcomes, published human studies have generally used 25–300mg of CBD daily. The most commonly referenced clinical study (Shannon et al., 2019, PMID: 30624194) used an average of 25–75mg daily in a naturalistic clinical setting. For sleep outcomes, the same dose range applies in most published research. For pain, most human studies have used 100mg or higher, with the strongest evidence from studies using cannabis products containing both CBD and THC.
A product delivering 10mg of CBD per gummy at one gummy per day delivers 10mg — below the range used in most anxiety and sleep studies. This does not mean the product is ineffective; individual sensitivity varies, and some consumers report effects at lower doses. But it does mean the product cannot be directly validated by the published clinical literature, which is worth knowing before attributing benefits to a specific product or dose.
Red Flags: What Poor Transparency Looks Like
The following patterns appear consistently in CBD products with below-average transparency practices. None of these automatically means the CBD in the product is ineffective, but each represents a verification gap that prevents a buyer from making a fully informed decision.
No COA available publicly. A brand that does not provide third-party test results has not independently verified what is in its product. This is the single highest-priority transparency gap.
Per-dose CBD not disclosed. Labels that show only a per-bottle total (e.g., “500MG”) without per-gummy disclosure prevent dose tracking and research comparison. Some brands describe per-bottle totals in ways that a casual reader might interpret as per-dose amounts — check the Supplement Facts panel specifically, not the front-of-label claim.
Fabricated statistics. Claims of “98% reduction in pain” or “67% increase in cognitive performance” with no cited source are not credible. These figures do not correspond to any identifiable published study. Their presence in marketing materials is a signal that the brand is not operating from an evidence-based framework.
Disease treatment claims. Marketing that says CBD “cures,” “treats,” “prevents,” or “diagnoses” any medical condition violates FDA dietary supplement regulations. Legitimate supplement marketing uses structure/function language: “may support,” “is associated with,” “research suggests.”
Full-spectrum and THC-free claims on the same product. As described above, these are mutually exclusive. Their co-appearance is a label inconsistency that a COA can resolve — but the inconsistency itself is a transparency signal. For an example of this pattern in a reviewed product, the Global Health Farms CBD Gummies review on this site documents this inconsistency with specifics.
A Pre-Purchase Checklist
Before placing any CBD order, the following five checks take less than ten minutes and materially improve the quality of your purchase decision. Does the Supplement Facts panel disclose per-serving CBD milligrams? Is a current third-party COA publicly available with a batch number that can be matched to the product? Does the COA cannabinoid profile confirm the labeled CBD amount within 15%? Does the COA show the THC level consistent with the formulation claim (trace THC for full-spectrum, non-detected for broad-spectrum)? Does the contaminant panel show pass results for heavy metals and pesticides?
Products that pass all five checks exist in the CBD market. They are not all premium-priced options. Transparency is a brand practice decision, not a cost-of-goods constraint. A product without a publicly available COA from an accredited lab is asking you to trust marketing claims that have not been independently verified — which is, at minimum, a reason to look at what else is available before committing to a multi-bottle purchase.
For a side-by-side look at how specific full-spectrum CBD products compare on these criteria, the full-spectrum CBD gummies comparison on this site covers the evaluation. For the safety and drug interaction considerations that apply regardless of which product you choose, the CBD safety and drug interactions guide is the relevant companion read. For the research context behind dose ranges and outcome evidence, the CBD research overview covers published study findings by outcome category.
Frequently Asked Questions
What is a Certificate of Analysis for CBD and why does it matter?
A Certificate of Analysis (COA) is a document produced by an independent third-party laboratory that tested a specific batch of a CBD product. It reports the actual measured cannabinoid content, contaminant screening results, and moisture content. It matters because CBD product labels are not verified by any federal regulatory body before a product goes to market. A brand can print any milligram amount on a label without testing it. A COA from an accredited third-party lab is the only way to confirm that the CBD content claimed on the label matches what is actually in the product, that THC levels fall within legal limits, and that the product does not contain harmful contaminants.
What is the difference between full-spectrum, broad-spectrum, and CBD isolate?
Full-spectrum CBD retains all naturally occurring cannabinoids from the hemp plant, including trace THC (under 0.3% delta-9 THC). Broad-spectrum removes THC while retaining other minor cannabinoids and terpenes. CBD isolate is pure cannabidiol with all other compounds removed. A product that claims to be simultaneously “full spectrum” and “THC-free” contains a contradiction: true full-spectrum hemp by definition contains trace THC. If you see both claims on one product, request the COA before purchasing.
How do I verify CBD milligrams per gummy from a label?
Find the Supplement Facts panel. The serving size and CBD milligrams per serving should both be listed. Divide the total CBD per bottle by the number of servings to cross-check: if a bottle lists 1000MG total CBD and 30 servings, each serving should contain approximately 33mg of CBD. If only a per-bottle total is given without a per-serving breakdown, the per-dose amount is not disclosed — you cannot compare this product to clinical research or accurately track your daily intake.
What are the biggest red flags on a CBD product label or website?
The most significant red flags: no Certificate of Analysis available; per-dose CBD milligrams not disclosed; marketing language claiming to “cure,” “treat,” or “diagnose” any disease; contradictory claims such as “full spectrum” and “THC-free” on the same product; fabricated statistics with no cited source; and testimonials describing replacing prescription medications. These are signals that a brand's transparency practices fall below the standard that allows an informed decision.
TotalHealthRD.com is an independent health information publication. Nothing published here constitutes medical advice. Consult a qualified healthcare provider before starting any supplement. This article contains no affiliate links. These statements have not been evaluated by the Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.